← Leaderboards
Susan Marie Graham
University Of Washington
$6,599,661
Attributed
$10,559,827
Total exposure
10
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.7M · FY2006–25$5M$3.8M$2.5M$1.3M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,188,579 · 11
By mechanism
R01$7,161,829 · 3
P30$3,188,833 · 2
R34$1,264,749 · 2
R21$915,488 · 2
K23$632,680 · 1
R13$25,000 · 1
Top collaborators
- Eduard Sanders8 shared
- Jane Marie Simoni4 shared
- Gary W Harper3 shared
- Jose Aron Lopez2 shared
Most similar at University Of Washington
Same institution · by research overlap
- Keshet Ronen$4,628,139
- Thomas M Burbacher$17,165,331
- Sarah Cusworth Walker$1,070,943
- Timothy Ryan Watkins$799,354
- Jashvant D Unadkat$14,909,800
Others in their field
Top investigators on “Resources”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$688,986,350
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Eric S Lander · Whitehead Institute For Biomedical Res$341,717,134
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$311,514,701
Research focus
ResourcesWashingtonUniversitiesKenyaAntiretroviral TherapyAfrica South Of The SaharaResearch PersonnelHiv InfectionsClinicCaringPublic HealthAids PreventionInnovationProviderDiagnosisScale UpBaseAcquired Immunodeficiency SyndromeViral Load ResultParticipantPersonsCountryDesignEpidemic
Grant awards (33)
WHO-recommended Periodic Presumptive Treatment versus Doxycycline Post-Exposure Prophylaxis for STI Control among Cisgender Men Who Have Sex with Men in Kenya$646,815
R01 · FY2025 · AI · contact PI
WHO-recommended Periodic Presumptive Treatment versus Doxycycline Post-Exposure Prophylaxis for STI Control among Cisgender Men Who Have Sex with Men in Kenya$290,440
R01 · FY2025 · AI · contact PI
WHO-recommended Periodic Presumptive Treatment versus Doxycycline Post-Exposure Prophylaxis for STI Control among Cisgender Men Who Have Sex with Men in Kenya$257,502
R01 · FY2025 · AI · contact PI
University of Washington Developmental AIDS Research Center for Mental Health (UW ARCH)$1,407,886
P30 · FY2024 · MH · contact PI
WHO-recommended Periodic Presumptive Treatment versus Doxycycline Post-Exposure Prophylaxis for STI Control among Cisgender Men Who Have Sex with Men in Kenya$1,245,739
R01 · FY2024 · AI · contact PI
University of Washington Developmental AIDS Research Center for Mental Health (UW ARCH)$971,811
P30 · FY2023 · MH · contact PI
Administrative Core$560,081
P30 · FY2023 · MH · contact PI
Acceptability of Sustained-Release Antiretrovirals for Treatment in the US and sub-Saharan Africa$367,416
R01 · FY2023 · MH · contact PI
University of Washington Developmental AIDS Research Center for Mental Health (UW ARCH)$249,055
P30 · FY2023 · MH · contact PI
Acceptability of Sustained-Release Antiretrovirals for Treatment in the US and sub-Saharan Africa$521,931
R01 · FY2022 · MH · contact PI
Acceptability of Sustained-Release Antiretrovirals for Treatment in the US and sub-Saharan Africa$548,545
R01 · FY2021 · MH · contact PI
Shikamana PrEP: A Community Participatory Approach to Integrating PrEP, Sexual Health, and Mental Health Services for GBMSM in Kenya$202,185
R34 · FY2021 · MH · contact PI
Acceptability of Sustained-Release Antiretrovirals for Treatment in the US and sub-Saharan Africa$441,832
R01 · FY2020 · MH · contact PI
Shikamana PrEP: A Community Participatory Approach to Integrating PrEP, Sexual Health, and Mental Health Services for GBMSM in Kenya$231,627
R34 · FY2020 · MH · contact PI
Social Frailty among Older Kenyan Women Living with and without HIV Infection$194,375
R21 · FY2020 · AG · contact PI
Principles of STI/HIV Research Course$25,000
R13 · FY2020 · AI · contact PI
Impact of a novel screening program to detect acute and prevalent HIV infection and reduce HIV transmission$561,795
R01 · FY2019 · AI · contact PI
Acceptability of Sustained-Release Antiretrovirals for Treatment in the US and sub-Saharan Africa$525,780
R01 · FY2019 · MH · contact PI
Social Frailty among Older Kenyan Women Living with and without HIV Infection$233,250
R21 · FY2019 · AG · contact PI
Shikamana PrEP: A Community Participatory Approach to Integrating PrEP, Sexual Health, and Mental Health Services for GBMSM in Kenya$204,244
R34 · FY2019 · MH · contact PI
Impact of a novel screening program to detect acute and prevalent HIV infection and reduce HIV transmission$576,362
R01 · FY2018 · AI · contact PI
Impact of a novel screening program to detect acute and prevalent HIV infection and reduce HIV transmission$572,643
R01 · FY2017 · AI · contact PI
Impact of a novel screening program to detect acute and prevalent HIV infection and reduce HIV transmission$605,029
R01 · FY2016 · AI · contact PI
Endothelial Activation and Microangiopathy in HIV-related Cardiovascular Disease$215,207
R21 · FY2016 · HL · contact PI
Endothelial Activation and Microangiopathy in HIV-related Cardiovascular Disease$272,656
R21 · FY2015 · HL · contact PI
Provider and Peer Support Intervention to Improve ART Adherence among Kenyan Men$199,273
R34 · FY2015 · MH · contact PI
Provider and Peer Support Intervention to Improve ART Adherence among Kenyan Men$199,273
R34 · FY2014 · MH · contact PI
Provider and Peer Support Intervention to Improve ART Adherence among Kenyan Men$228,147
R34 · FY2013 · MH · contact PI
Genital HIV-1 Shedding among Women Starting Second-Line Antiretroviral Therapy$126,671
K23 · FY2010 · AI · contact PI
Genital HIV-1 Shedding among Women Starting Second-Line Antiretroviral Therapy$126,440
K23 · FY2009 · AI · contact PI
Genital HIV-1 Shedding among Women Starting Second-Line Antiretroviral Therapy$126,216
K23 · FY2008 · AI · contact PI
Genital HIV-1 Shedding among Women Starting Second-Line Antiretroviral Therapy$126,791
K23 · FY2007 · AI · contact PI
Genital HIV-1 Shedding among Women Starting Second-Line Antiretroviral Therapy$126,562
K23 · FY2006 · AI · contact PI